LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

July 29, 2025 | Last Trade: US$27.76 0.06 -0.22

SAN DIEGO, July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, recognizing excellence in customer satisfaction across key performance areas.

  • Awards:
    • Chemistry
      • Best overall system performance
    • Integrated Systems
      • Best overall system performance
      • Best overall service

QuidelOrtho Corporation | 2025 IMV ServiceTrak Awards

  • Top Rankings:
    • QuidelOrtho received top rankings in several key categories for Integrated Systems, including:
      • #1 Overall Net Promoter Score (NPS) by Manufacturer
      • #1 Overall Manufacturer Performance
      • #1 Overall Service Engineer Performance
      • #1 Overall Training Performance

QuidelOrtho invested in initiatives focused on what customers value most, driving significant advances in reliability, product quality and service. This commitment delivered a 17-point increase in NPS, the largest gain in the category, reflecting higher customer loyalty and satisfaction.

Learn how QuidelOrtho prioritizes customers' beliefs and values to deliver solutions.

These awards and rankings showcase QuidelOrtho's comprehensive approach to enhancing both product and service in clinical diagnostics. A key part of this success has been investing in employee development through specialized customer experience training, fueling continued progress and stronger relationships with customers.

QuidelOrtho remains committed to ongoing innovation and delivering smart, customer-focused solutions that elevate laboratory efficiency and outcomes.

Key Quotes:

Karen Taylor, Senior Vice President, Customer Experience, QuidelOrtho

"We're honored to be recognized with three awards and top rankings in this year's IMV ServiceTrak Awards, but even more so, we're grateful to our customers for their ongoing trust and collaboration. These results reflect their feedback and our shared commitment to improving outcomes together. Our QuidelOrthoCQ™ solutions are designed to give customers the freedom to focus on what matters most. We'll continue listening and evolving to better support their success."

Additional Resources:

About IMV ServiceTrak

The IMV ServiceTrak Clinical Laboratory Awards are the result of independent market research assessing manufacturer performance in the in-vitro diagnostics space. IMV's annual report represents an independent analysis of customer satisfaction with instrument manufacturers, system performance and service received.

IMV's ServiceTrak Clinical Laboratory Awards are based on feedback from laboratory testing professionals in 1,800 clinical testing locations, representing 4,100 instruments. For over 25 years, IMV ServiceTrak has provided independent analysis of service trends and manufacturer ratings in laboratory diagnostics.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation and accessibility. Learn more at www.quidelortho.com.

Investor Contact:

Media Contact:

Juliet Cunningham

D. Nikki Wheeler

Vice President, Investor Relations         

Senior Director, Corporate

This email address is being protected from spambots. You need JavaScript enabled to view it.

Communications

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page